SGO 2023

Conference Coverage

Uterine Cancer Mortality on the Rise, but Research Remains Underfunded

Though mortality rates for uterine cancer are on the rise, research for this cancer is underfunded, a study suggests.

PIK3CA and ARID1A May Be Therapeutic Targets in Advanced Cervical Cancer

PIK3CA and ARID1A may be targets for drug development in recurrent or metastatic cervical cancer, according to researchers.

More Lines of Chemotherapy Linked to Higher Risk of VTE in Ovarian Cancer

New research suggests that, for patients with ovarian cancer, the risk of VTE increases as patients receive more lines of chemotherapy.

Abortion Restrictions May Affect More than 20% of Pregnant Cancer Patients in the US

More than 20% of US patients diagnosed with cancer during pregnancy may be unable to terminate that pregnancy due to abortion laws in their state, a new study suggests.

Time Spent on Health Care for Endometrial Cancer Negatively Affects Quality of Life

Patients with advanced or recurrent endometrial cancer spend about 15% of their time addressing health care needs, and this time burden can have a negative effect on their quality of life, a study suggests.

Minimally Invasive Surgery Linked to Longer Survival in Advanced Ovarian Cancer

Patients with advanced ovarian cancer may live longer if they undergo minimally invasive surgery rather than laparotomy, a study suggests.

Overall Survival Similar With or Without Niraparib Maintenance in Ovarian Cancer

Niraparib maintenance does not improve overall survival in patients with platinum-sensitive recurrent ovarian cancer, updated data suggest.

Dostarlimab Plus Chemo Deemed New Standard Care for Endometrial Cancer

Adding dostarlimab to chemotherapy can improve outcomes in patients with primary advanced or recurrent endometrial cancer, a phase 3 trial suggests.

Durvalumab, Tremelimumab, and Chemo Deemed Active in Advanced Ovarian Cancer

The combination of durvalumab, tremelimumab, and chemotherapy can produce durable responses in patients with newly diagnosed, advanced-stage epithelial ovarian cancer, a phase 2 trial suggests.

Adavosertib Appears Active but Toxic in Advanced Uterine Cancer

Adavosertib is active but not well tolerated in patients with recurrent or persistent uterine serous carcinoma, a phase 2 study suggests.

Pembrolizumab Improves PFS in Advanced, Recurrent Endometrial Cancer

Adding pembrolizumab to chemotherapy improves progression-free survival in advanced or recurrent endometrial cancer, a phase 3 trial suggests.

Adding Anlotinib to Pembrolizumab Improves PFS in Ovarian Cancer

Anlotinib enhances the efficacy of pembrolizumab in patients with recurrent or refractory high-grade serous ovarian cancer, a phase 2 study suggests.

No Difference Between Chemoradiotherapy and Chemo Alone in Endometrial Cancer

Chemoradiotherapy does not improve overall survival, compared with chemotherapy alone, in patients with locally advanced endometrial cancer, a phase 3 trial suggests.

Toripalimab, Bevacizumab, and Chemo Deemed Effective in Advanced Cervical Cancer

The combination of toripalimab, bevacizumab, and platinum-based chemotherapy appears safe and effective for patients with advanced cervical cancer.

Clinical Trial Participation Linked to Longer OS in Platinum-Resistant Ovarian Cancer

Patients with platinum-resistant epithelial ovarian cancer may have better overall survival if they enroll on a clinical trial than if they receive standard care.

54 Million US Women May Lack Access to a Gynecologic Oncologist 

The number of gynecologic oncologists in the US has grown in recent years, but many patients still lack access to a gynecologic oncologist.

Reimbursement for Gynecologic Oncology Procedures Has Not Kept Up With Inflation

Physician reimbursement rates for gynecologic oncology procedures have increased in recent years but have not kept up with inflation, a study suggests.

Gemcitabine Plus Cisplatin and IMRT Produces Complete Responses in Vulvar Cancer

The combination of gemcitabine, cisplatin, and IMRT appears effective in patients with locally advanced, unresectable vulvar cancer.

Cryocompression May Reduce Peripheral Neuropathy in Gynecologic Cancer

Cryocompression can reduce subjective peripheral neuropathy in patients with gynecologic cancer undergoing chemotherapy, a study suggests.

Ribociclib Plus Letrozole Yields Responses in Recurrent Ovarian Cancer

Ribociclib plus letrozole elicits responses in patients with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum, a phase 2 study suggests.